Aspeya
Mo Aydin is a highly experienced professional in pharmaceutical development, currently serving as the Head of Pharmaceutical Development and Global Head of Inhaled Platform Support at Aspeya since December 2021. Prior roles include Senior Director of Pharmaceutical Development at Theravance Biopharma US, Inc., and Director of Pharmaceutical Development at Insmed Incorporated. Mo has also held key positions at Teva Pharmaceuticals, MicroDose Therapeutx, and Catalent/Cardinal Health/Magellan Labs, showcasing a strong background in respiratory research and development. Mo's academic credentials include a Ph.D. in Inhalation Science from the University of Bath and a B.Sc. (Hons) in Chemical & Pharmaceutical Sciences from the University of Sunderland.
This person is not in any teams
This person is not in any offices
Aspeya
We are on a journey to empower healthier lifestyles and target specific unmet needs. We do this by being innovative, optimizing formulas, and applying rigorous scientific standards. This involves harnessing deep insight and scientific substantiation to reimagine how ingredients can be used, and working towards the development and commercialization of a pipeline of wellness and healthcare products and brands. We are applying our expertise to innovate in four areas of focus: Consumer health, cannabinoids, inhaled therapeutics, and nicotine replacement therapy. Our people are open-minded thinkers, leading-edge scientists, and knowledgeable innovators. Want to join our team? Visit our careers site to search for opportunities: careers.aspeya.com